Boston Scientific (BSX) Could Be 27% Below Fair Value After Earnings Guidance Cut

Boston Scientific (BSX) moved into focus after third quarter 2026 results, as modest sales of US$5.14b and net income of US$582m met a sharply lower market reaction and fresh earnings guidance.

The sharp 1-day share price decline of 5.84% brings Boston Scientific to US$42.43, capping a weak run in which the share price return is down 7.76% over 90 days and the 1-year total shareholder return has fallen 57.70%. This suggests sentiment has faded as investors reassess risk after the cyberattack, recall and trimmed guidance.

See how Boston Scientific's selloff compares with other medical device peers by jumping over to our curated list of list of solid balance sheet and fundamentals (24 results) .

Boston Scientific now trades sharply below both its average analyst target and one intrinsic value estimate, creating a wide gap between market price and modeled worth. The key question is where in that range fair value truly lies next.

Most Popular Narrative: 27% Undervalued

Boston Scientific's most followed valuation storyline puts fair value at $57.82, well above the latest $42.43 close. This frames a wide discount that investors now have to reconcile with cyber, recall and guidance headwinds.

The current valuation implies the market is discounting the shares for near term growth and margin pressure more than this narrative judges warranted, given the planned restructuring savings, capital returns, and expansion into large adjacencies. Based on this view, Boston Scientific is considered undervalued with a positive outlook.

See why 88 investors see Boston Scientific as 27% undervalued .

Result: Fair Value of $57.82 (UNDERVALUED)

Still, this narrative can crack if softness in Electrophysiology and WATCHMAN persists or if the US$14.5b Penumbra deal and broader restructuring underdeliver.

Find out about the key risks to this Boston Scientific narrative .

Next Steps

Mixed signals around Boston Scientific's selloff and valuation gap only matter if you act on the data yourself and stress test the story in your own way, starting with the 5 key rewards and 1 important warning sign .

Looking for more ideas beyond Boston Scientific?

If Boston Scientific has you rethinking risk and reward, do not stop here. Widen your watchlist now and give yourself more options before the next move.

• Target resilient balance sheets first and scan a list of solid balance sheet and fundamentals (24 results) that filters for companies with stronger financial foundations.

• Hunt for mispriced opportunities by reviewing a curated 26 high quality undervalued stocks that focuses on quality businesses trading below modeled worth.

• Prioritize stability and income by checking a 6 dividend fortresses designed for investors who want higher yields with an emphasis on durability.